<DOC>
	<DOCNO>NCT00686634</DOCNO>
	<brief_summary>This study compare effect new oral agent type 2 diabetes , sitagliptin , comparison thiazolidinediones third-line oral agent , patient type 2 diabetes mellitus .</brief_summary>
	<brief_title>Sitagliptin Combination With Metformin Sulfonylurea</brief_title>
	<detailed_description>The aim protocol determine non-inferiority effectiveness sitagliptin compare control group patient treat thiazolidinediones add-on therapy , low-income ethnic minority type 2 diabetic patient fail maintain adequate control maximal dos metformin sulfonylurea agent .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Male female , age 1875 Type 2 diabetes At least 3 month treatment maximum tolerate dos metformin sulfonylurea agent , inadequate glycemic control ( Hemoglobin A1c ( HbA1c ) &gt; 7.0 % ) Able comply schedule visit requirement protocol Any contraindication use metformin sulfonylurea agent Extreme hyperglycemia symptom polyuria polydipsia Current previous chronic use insulin ( treatment gestational diabetes ) History confirm ( clinical suspicion ) type 1 diabetes mellitus Episodes symptomatic hypoglycemia average great per day Estimated glomerular filtration rate ( eGFR ) &lt; 60 mL/min Subjects active hemolytic anemia hemoglobin variant render measurement HbA1c unreliable History clinically significant hepatic , cardiovascular ( include use digoxin ) , major systemic disease may make use sitagliptin unsafe , otherwise make interpretation data difficult . Female subject childbearing potential sexually active use reliable form contraception Current pregnancy lactation . Subjects likely require initiate therapy drug may interfere glucose metabolism course study . Subjects another investigational study receive another investigational medication within 30 day study entry Subjects unable unwilling give inform consent , comply component study protocol , attend schedule followup visit , present barrier would make implementation protocol unusually difficult .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>sitagliptin</keyword>
	<keyword>type 2 diabetes</keyword>
	<keyword>combination therapy</keyword>
</DOC>